Plain-English translation of NCT04969835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which is a form of a chemotherapy drug designed to target cancer cells more specifically. Researchers want to find the safest and most effective dose of this medication for patients with advanced cancers that have not responded to standard treatments. The study will also measure how the body processes the medication and whether it helps shrink tumors.
Standard cancer treatments don't work for all patients, and they often cause severe side effects. This medication is designed to deliver chemotherapy more directly to cancer cells while sparing healthy tissue, potentially offering a better balance between effectiveness and safety.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive infusions of the new medication through your vein on a regular schedule—either every 3 weeks or every 2 weeks, depending on which group you are assigned to. You will have multiple clinic visits for blood tests, heart monitoring, and scans to check how your cancer is responding and watch for side effects. Treatment continues until your cancer progresses, side effects become too severe, or you reach a safe lifetime limit of this chemotherapy type.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
United Kingdom